Herpes Simplex Virus Treatment
According to Intent Market Research, the Herpes Simplex Virus (HSV1) Treatment Market is expected to grow from USD 2.1 billion in 2024-e at a CAGR of 6.9% to touch USD 3.3 billion by 2030. The Herpes Simplex Virus (HSV1) Treatment Market is dominated by key players such as GlaxoSmithKline plc, Roche Holding AG, Merck & Co., Inc., Pfizer Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Gilead Sciences, Inc., Bristol-Myers Squibb Company, Johnson & Johnson, AbbVie Inc., Amgen Inc., Sanofi S.A., Astellas Pharma Inc., Cipla Limited.